Molecular Pathology of Pancreatic Cancer

Cancer Journal

Volumn 7, Issue 4, 2001, Pages 251-258

  Hruban, Ralph H ^a,b   Iacobuzio Donahue, Christine ^a   Wilentz, Robb E ^a   Goggins, Michael ^a   Kern, Scott E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

DPC4; K ras; Oncogene; p16; p53; Pancreatic cancer; Tumor suppressor gene

Indexed keywords

MITOCHONDRIAL DNA;

ENZYMOLOGY; GENETICS; HUMAN; ONCOGENE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

DNA, MITOCHONDRIAL; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; PANCREATIC NEOPLASMS;

EID: 0035409076     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Hruban RH, Petersen GM, Ha PK, Kern SE Genetics of pancreatic cancer From genes to families Surg Oncol Clin N Am 1998;7: 1-23
2. Caldas C, Hahn SA, da Costa LT et al Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8:27-32
3. DiGiuseppe JA, Hruban RH, Goodman SN et al Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-688.
4. Goggins M, Shekher M, Kenan T et al Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas Cancer Res 1998;58:5329-5332
5. Goggins M, Schutte M, Lu J et al Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-5364
6. Hahn SA, Schutte M, Hoque ATMS et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21 1. Science 1996;271:350-353.
7. Redston MS, Caldas C, Seymour AB et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res 1994, 54:3025-3033.
8. Rozenblum E, Schutte M, Goggins M et al Tumor-suppressive pathways in pancreatic carcinoma Cancer Res 1997;57: 1731-1734
9. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 1997;57 3126-3130.
10. Su GH, Bansal R, Murphy KM et al. ACVRIB (ALK4, activin receptor type 1B) gene mutation in pancreatic carcinoma Proc Natl Acad Sci USA 2001;98 3254-3257
11. Bartsch D, Shevlin DW, Tung WS et al Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas Genes Chrom Cancer 1995;14:189-195.
12. Hu YX, Watanabe H, Ohtsubo K et al Frequent loss of p16 expression and its correlation with clinicopathologic parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-1477.
13. Naumann M, Savitskaia N, Eilert C et al Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996;110:1215-1224.
14. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998;395 237-243
15. Sellers WR, Rodgers JW, Kaelin WG. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA 1995;92 11544-11548
16. Barton CM, Staddon SL, Hughes CM et al Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-1082.
17. Berrozpe G, Schaeffer J, Peinado MA et al. Comparative analysis of mutations m the p53 K-ras genes in pancreatic cancer Int J Cancer 1994;58:185-191
18. Boschman C, Reddy JK, Rao MS Immunohistochemical analysis of p53 protein expression in human pancreatic ductal adenocarcinomas and precursor lesions. Lab Invest 1994;70
19. WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival Am J Clin Pathol 1998;110:16-23.
20. Lee EY, Cibull ML, Jennings CD Expression of p53 protein and cigarette smoking in pancreatic adenocarcinoma. Lab Invest 1994,70:133A-133A.
21. Lundin J, Nordling S, von Boguslawsky K et al Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer Oncology 1996;53 104-111
22. Nakamori S, Yashima K, Murakami Y et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma Jpn J Cancer Res 1998;86 174-181.
23. Pellegata NS, Sessa F, Ranault B et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions Cancer Res 1994;54 1556-1560.
24. Ruggeri B, Zhang S-Y, Caamano J et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes Oncogene 1992;7: 1503-1511.
25. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations Am J Pathol 1993;142: 1534-1543
26. Yonish-Rouach E, Resnitzky D, Lotem J et al. Wildtype p53 induces apoptosis of myeloid leukemic cells that is inhibited by interteukin-6 Nature 1991;352 345-347
27. Baker SJ, Markowitz S, Fearon ER et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-915
28. Bunz F, Dutriaux A, Lengauer C et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282: 1497-1501
29. Kastan MB, Onyekwere O, Sidransky D et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
30. Kern SE, Kinzler KW, Bruskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252 1708-1711
31. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88 323-331.
32. Vogelstein B, Kinzler KW p53 function and dysfunction. Cell 1992;70:523-526.
33. Dai JL, Turnacioglu KK, Schutte M et al Dpc4 transcriptional activation and dysfunction in cancer cells Cancer Res 1998;58: 4592-4597
34. de Winter JP, Roelen BA, ten Dijke P et al. DPC4 (SMAD4) mediates transforming growth factor-beta 1 (TGF-beta 1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997,14 1891-1899
35. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways Nature 1996;383 832-836
36. Wilentz RE, Su GH, Dai JL et al Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation Am J Pathol 2000;156: 37-43
37. Montgomery E, Goggins M, Zhou S et al Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor β(TGFβ) receptor defects Am J Pathol 2001;158:537-542
38. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types Cancer Res 1996;56:2527-2530.
39. Schutte M, Rozenblum E, Moskaluk CA et al. An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12 Cancer Res 1995,55 4570-4574.
40. Schutte M, daCosta LT, Hahn SA et al Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Nat Acad Sci USA 1995;92:5950-5954
41. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2 Nature 1995;378 789-792.
42. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Nat Cancer Inst 1998;90:978-985
43. Caamano J, Ruggeri B, Momiki S et al Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 1991;139:839-845.
44. Gayther SA, Gorringe KL, Ramus SJ et al Identification of germline E-cadherin mutations in gastric cancer families of European origin Cancer Res 1998;58:4086-4089.
45. Su GH, Hilgers W, Shekher M et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene Cancer Res 1998;53:2339-2342.
46. Su GH, Hruban RH, Bova GS et al Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-1840.
47. Ueki T, Toyota M, Sohn TA et al Hypermethylation of multiple genes in pancreatic carcinoma. Cancer Res 2000;60:1835-1839.
48. Hruban RH, van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinoma of the human pancreas A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-554.
49. Almoguera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554
50. Scarpa A, Capelli P, Villanueva A et al. Pancreatic cancer in Europe: Ki-ras gene mutation patterns show geographical differences Int J Cancer 1994;57:167-171
51. Smit VTHBM, Boot AJM, Smits AMM et al. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-7782
52. Batra SK, Metzgar RS, Hollingsworth MA Isolation and characterization of a complementary DNA (PD-1) differentially expressed by human pancreatic ductal cell tumors. Cell Growth Differentiation 1991;2:385-390
53. Cheng JQ, Ruggeri B, Klein WM et al Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorgenicity by antisense RNA. Proc Nad Acad Sci 1996;93: 3636-3641.
54. Ruggeri BA, Huang L, Wood M et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molec Carcinog 1998;21:81-86.
55. Solinas-Toldo S, Wallrapp C, Muller-Pillasch F et al Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization Cancer Res 1996;56:3803-3807
56. Wallrapp C, Müeller-Pillasch F, Solinas-Toldo S et al Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene Cancer Res 1997; 57:3135-3139.
57. Wilentz RE, Goggins M, Redston M et al. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: A newly described and characterized entity. Am J Pathol 2000;156:1641-1651.
58. + Am J Pathol 1998;152:1501-1507.
59. Jones JB, Song JJ, Hempen PM et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations Cancer Res 2001;61: 1299-1304
60. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours Nature 2000;406:747-752
61. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer N Engl J Med 2001;344 539-548.
62. Velculescu VE, Zhang L, Vogelstin B, Kinder KW. Serial analysis of gene expression Science 1995;270:484-487
63. Byungwoo R, Jones J, Hruban RH, Kern SE Invasion-specific genes in malignancy SAGE comparisons of primary and passaged cancers Cancer Res 2001;61:1833-1838.
64. Argani P, Rosty C, Reiter RE et al Discovery of new markers of cancer through serial analysis of gene expression (SAGE): Prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma Submitted for Publication, 2001
65. Zhou W, Sokoll LJ, Bruzek DJ et al. Identifying markers for pancreatic cancer by gene expression analysis Cancer Epidemiol Biomarkers Prev 1998;7 109-112
66. Westra WH, Sturm PJ, Drillenburg P et al K-ras oncogene mutations in osteoclast-like giant-cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 1998;22:1247-1254.
67. Berendt RC, Shnitka TK, Wiens E et al The osteoclast-type giant cell tumor of the pancreas. Arch Pathol Lab Med 1987;111: 43-48.
68. Rosai J. Carcinoma of pancreas simulating giant cell tumor of bone Electron-microscopic evidence of its acinar cell origin. Cancer 1968;22:333-344.
69. Molberg KH, Heffess C, Delgado R, Albores-Saavedra J. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region Cancer 1998;82:1279-1287.
70. van den Berg W, Tascilar M, Offerhaus GJA et al. Pancreatic mucinous cystic neoplasms with sarcomatous stroma: Molecular evidence for monoclonal origin with subsequent divergence of the epithelial and sarcomatous components Mod Pathology 1999;13: 86-91
71. Hruban RH, Goggins M, Parsons JL, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-2972.
72. Cubilla AL, Fitzgerald PJ Morphological lesions associated with human primary invasive nonendocrine pancreas cancer Cancer Res 1976;36:2690-2698.
73. Furukawa T, Chiba R, Koban M et al. Varying grades of epithelial atypia in the pancreatic ducts of humans Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen Arch Pathol Lab Med 1994;118:227-234.
74. Kozuka S, Sassa R, Taki T et al Relation of pancreatic duct hyperplasia to carcinoma Cancer 1979;43:1418-1428
75. Sommers SC, Murphy SA, Warren S. Pancreatic duct hyperplasia and cancer. Gastroenterology 1954;27 629-640.
76. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-169
77. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia. Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-2006.
78. Goggins M, Hruban RH, Kern SE BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications Am J Pathol 2000;156:1767-1771.
79. Wilentz RE, Geradts J, Maynard R et al Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions Loss of intranuclear expression Cancer Res 1998;58:4740-4744.
80. Hameed M, Marrero AM, Conlon KC, Brennan MF, Klimstra DS Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: An immunohistochemical analysis of 100 cases. Lab Invest 1994;70:132A
81. Lüttges J, Galehdari H, Schwarte-Waldhoff I et al Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis Am J Pathol 2001.
82. Hruban RH, Adsay NV, Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia (PanIN) A new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 2001.
83. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12
84. Sturm PD, Rauws EA, Hruban RH et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999;5:629-635.
85. Casey G, Yamanka Y, Friess H et al p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis Cancer Lett 1993;69:151-160.
86. Iwao T, Itoh M, Tsuchida A et al. Detection of p53 protein in cytological specimens of pancreatic diseases obtained by selective endoscopic brushing. Gastroenterology 1995;108:A361-
87. Sturm PDJ, Hruban RH, Ramsoekh TB et al. The potential diagnostic use of k-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186:247-253
88. Tascilar M, Sturm PDJ, Caspers E et al Diagnostic p53 immunostaining of endobiliary brush cytology. Preoperative cytology compared with the surgical specimen. Cancer 1999;87:306-311.
89. van Es JM, Polak MM, van den Berg FM et al. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product J Clin Pathol 1995;48:218-222.
90. Xu J, Attisano L Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000;97:4820-4825
91. Lynch HT, Smyrk T, Kern SE et al. Familial pancreatic cancer: a review Semin Oncol 1996;23:251-275.
92. Lumadue JA, Griffin CA, Osman M, Hruban RH Familial pancreatic cancer and the genetics of pancreatic cancer Surg Clin N A 1995;75:845-855
93. Tersmette AC, Petersen GM, Offerhaus GJ et al Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-744.
94. Lal G, Liu G, Schmocker B et al. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 2000;60 409-416
95. Lynch HT, Brand RE, Lynch JF et al. Genetic counseling and testing for germ-line p16 mutations in two pancreatic cancer-prone families Case report Gastroenterology 2000;119:1756-1760.
96. White K, Held KR, Weber BHF A BRCA2 germ-line mutation in familial pancreatic carcinoma. Int J Cancer 2001;91:742-744.
97. Wilentz RE, Chung CH, Sturm PDJ et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma Cancer 1998;82:96-103.
98. Wilentz RE, Slebos RJC, Hruban RH Screening for pancreatic cancer using techniques to detect altered gene products. In: Reber HA, ed Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment Totowa, NJ: Humana Press, Inc , 1997:113-136.
99. Caldas C, Hahn SA, Hruban RH et al Dectection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia Cancer Res 1994;54:3568-3573.
100. Eguchi S, Kohara N, Komuta K, Kanematsu T Mutation of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;77(suppl):1707-1710
101. Sidransky D, von Escheribach A, Tsai Y et al. Identification of p53 gene mutations in bladder cancers and urine samples Science 1991;252:706-709
102. Hruban RH, van der Riet P, Erozan Y, Sidransky D. Molecular biology and the early detection of carcinoma of the bladder - the case of Hubert H. Humphrey. N Eng J Med 1994;330:1276-1278.
103. Gutiérrez AA, Martinez F, Mas-Oliva J. Identification of K-ras mutations in pancreatic juice Ann Intern Med 1996;124: 1014-1015
104. Iguchi H, Sugano K, Fukayama N et al. Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer Gastroenterology 1996;110 221-226.
105. Kondo H, Sugano K, Fukayama N et al. Detection of K-ras gene mutations at condon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-905.
106. Malats N, Porta M, Fernandez E, Real FX RE: Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas J Natl Cancer Inst 1994;86:1353-1354.
107. Mulcahy HE, Lyautey J, Lederrey C et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients Clin Cancer Res 1998;4 271-275
108. Pasricha PJ ERCP meets C-K-ras towards an improved diagnosis of pancreatic cancer. Gastroenterology 1996;110:311-317.
109. Theodor L, Melzer E, Sologov M et al Detection of pancreatic carcinoma diagnostic value of K-ras mutations in circulating DNA from serum Digest Dis Sci 1999;44 2014-2019
110. Watanabe H, Sawabu N, Songúr Y et al Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis. Pancreas 1996;12: 18-24
111. Abbruzzese JL, Evans DB, Raijman I et al Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer Anticancer Res 1997;17:795-802
112. Ko SC, Gotoh A, Thalmann GN et al Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model Hum Gene Ther 1996;7 1683-1691